Janux Therapeutics (Janux Therapeutics) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Janux Therapeutics Days Sales Outstanding?

Janux Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $0.00 Mil. Janux Therapeutics's Revenue for the three months ended in Dec. 2023 was $2.46 Mil. Hence, Janux Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Janux Therapeutics's Days Sales Outstanding or its related term are showing as below:

JANX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.22 Med: 802.86 Max: 802.86
Current: 28.22

During the past 5 years, Janux Therapeutics's highest Days Sales Outstanding was 802.86. The lowest was 28.22. And the median was 802.86.

JANX's Days Sales Outstanding is ranked better than
87.11% of 892 companies
in the Biotechnology industry
Industry Median: 72.19 vs JANX: 28.22

Janux Therapeutics's Days Sales Outstanding declined from Dec. 2022 (16.04) to Dec. 2023 (0.00).

Janux Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Janux Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Janux Therapeutics Days Sales Outstanding Chart

Janux Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

802.86

Janux Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial												16.04	33.42	64.75	-	-

Competitive Comparison of Janux Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Janux Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Janux Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's Days Sales Outstanding falls into.

Janux Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Janux Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	8.083	*	365
=	0					/	8.083	*	365
=	0.00

Janux Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	2.461	*	365 / 4
=	0					/	2.461	*	365 / 4
=	0.00

Janux Therapeutics (NAS:JANX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Janux Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Janux Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Janux Therapeutics (Janux Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130

Website

https://www.januxrx.com

Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.

Executives

Tighe Reardon	10 percent owner, officer: Acting Chief Financial Officer	C/O SYNTHORX, INC., 11099 NORTH TORREY PINES ROAD, SUITE 190, LA JOLLA CA 92037
Avalon Ventures Xi, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Jay Lichter	director, 10 percent owner	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Charles M. Winter	officer: Chief Technical Officer	C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO CA 92130
Winston Kung	director	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Byron Robinson	officer: Chief Strategy Officer	C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Capital Gp Viii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Capital Gp Vii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alana B. Mcnulty	director	C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
Ronald W Barrett	director	C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051